A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on a critical issue in cancer care: routine clinical reads are more prone to overdiagnosing progressive disease when compared to RECIST 1.1 interpretations. This discrepancy holds significant implications, potentially leading to the premature discontinuation of effective treatments for cancer clinical trial participants and patients under standard care.
In this study, mint Lesion software was utilized for the criteria-based reads, determining overall response assessments according to RECIST 1.1 criteria, and generating structured reports for the clinical trial's principal investigator.
To learn more about the study's insights into the discrepant assessments and the suggested steps for mitigating this issue, click here.
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
Related Resources
Related Resources
Data Analytics and Instant-Trial Research
Context-driven read procedures in mint Lesion™ facilitate the generation of well-structured data on a large scale. At RSNA 2016, Mint Medical presents…
Leipzig shines as new host for German Radiology Congress
4 days full of sun – there couldn’t be any better circumstances for Leipzig to present itself as new host of the German Radiology Congress. Mint…
ECR 2016 in Vienna – Structured Reporting awakens
The ECR 2016 in Vienna achieved a new record in number of participants: 25.998 people visited the congress. Mint Medical also realized a personal best…